← Back to Influence Map
Entity DossierOrganization
ABBVIE INC.
DC · US
Biopharmaceutical company
pharmaceuticals
Tracked direct giving
$0
LDA reported lobbying spend
$10,380,000
Connections
11
Lobbying Activity Detail
Disclosed lobbying expenditures from LDA filings where this entity is the client. Dollar amounts represent what was reported to the Senate Office of Public Records.
Top Lobbying Issues
HCRHealth Issues
$18.9MMMMMedicare/Medicaid
$17.4MTAXTaxation/Internal Revenue Code
$15.9MCPTCopyright/Patent/Trademark
$15.1MLBRLabor/Employment
$11.2MTRDTrade
$6.8MPHAPharmacy
$680KBUDBudget/Appropriations
$600KMEDMedical/Disease Research
$400KLobbying Firms Retained
In-house lobbyists (filed as its own registrant)$14.9M
TARPLIN, DOWNS & YOUNG, LLC$840K
W STRATEGIES, LLC$700K
FEDERAL STREET STRATEGIES, LLC$700K
CORNERSTONE GOVERNMENT AFFAIRS, INC.$700K
MARSHALL & POPP, LLC$620K
Baker & Hostetler LLP$470K
CHECKMATE GOVERNMENT RELATIONS$180K
WILLIAMS AND JENSEN, PLLC$60K
Lobbying data from Senate LDA filings and the LobbyView dataset (MIT/NSF, CC-BY-4.0). Dollar figures represent disclosed expenditures only and may not capture all influence activity. Issue codes follow the LDA general issue classification.
Connection Graph
0 nodes · 0 edgesHover for labels · Double-click to expand
Loading graph...
Person
Organization
PAC
Gov Body
Legislature
Think Tank
Industry
Outcome
Click a node to see details
Double-click to expand its connections
Relationships
| Type | Connected To | Details | Source |
|---|---|---|---|
| Lobbied on | Inflation Reduction Act - Energy Provisions (H.R.5376) | LDA filing: lobbied on Inflation Reduction Act - Energy, period 1st Quarter (Jan 1 - Mar 31), reported amount $2,110,000 | Source |
| Lobbied on | Inflation Reduction Act - Drug Pricing Provisions (H.R.5376) | LDA filing: lobbied on IRA Drug Pricing Provisions, period 1st Quarter (Jan 1 - Mar 31), reported amount $2,110,000 | Source |
| Retained | CORNERSTONE GOVERNMENT AFFAIRS, INC. | Hired CORNERSTONE GOVERNMENT AFFAIRS, INC. to lobby on Pharmaceuticals | Source |
| Commented on | Centers for Medicare & Medicaid Services | Public comment on CMS-2023-0092: Medicaid Program: Misclassification of Drugs, Program Administration and Program Integrity Updates under the Medicaid Drug Rebate Program | Source |
| Retained | TARPLIN, DOWNS & YOUNG, LLC | Hired TARPLIN, DOWNS & YOUNG, LLC to lobby (1st Quarter (Jan 1 - Mar 31) 2023) | Source |
| Retained | Baker & Hostetler LLP | Hired BAKER & HOSTETLER LLP to lobby (1st Quarter (Jan 1 - Mar 31) 2023) | Source |
| Retained | W STRATEGIES, LLC | Hired W STRATEGIES, LLC to lobby (1st Quarter (Jan 1 - Mar 31) 2023) | Source |
| Retained | FEDERAL STREET STRATEGIES, LLC | Hired FEDERAL STREET STRATEGIES, LLC to lobby (1st Quarter (Jan 1 - Mar 31) 2023) | Source |
| Retained | MARSHALL & POPP, LLC | Hired MARSHALL & POPP, LLC to lobby (3rd Quarter (July 1 - Sep 30) 2023) | Source |
| Retained | WILLIAMS AND JENSEN, PLLC | Hired WILLIAMS AND JENSEN, PLLC to lobby (1st Quarter (Jan 1 - Mar 31) 2026) | Source |
| Retained | CHECKMATE GOVERNMENT RELATIONS | Hired CHECKMATE GOVERNMENT RELATIONS to lobby (1st Quarter (Jan 1 - Mar 31) 2026) | Source |